Nilvadipine
Syk inhibitor and Ca channel blocker / A novel DHP L-type Ca2+ channel blocker that also inhibits Syk.1 Blocks Aβ production, APPβ secretion and reduces BACE-1 expression in CHO cells over-expressing Aβ in vitro. Enhances clearance of Aβ across the blood brain barrier in vivo. Reduces brain Aβ levels in a mouse tauopathy model.1 Clinically useful antihypertensive agent.2 Has been shown to prevent cognitive decline in some clinical trials.3 Produces a protective effect on glutamate neurotoxicity in retinal ganglion cells, an effect not shared by other L-type Ca2+ channel blockers such as nifedipine and diltiazem.4
Biochemicals & reagents
75530-68-6
FR34235
1) Paris et al. (2014), The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation; J.Biol.Chem. 289 33927 2) Rosenthal (1994), Nilvadipine: profile of a new calcium antagonist. An overview; J.Cardiovasc.Pharmacol. 24 Suppl 2:S92 3) Nimmrich and Eckert (2013), Calcium channel blockers and dementia; Br.J.Pharmacol. 169 1203 4) Otori et al. (2003), Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells; Brain Res. 961 213
-20°C
TARGET: Kinase; Ion channel -- PATHWAY: Calcium signaling -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration; Hypertension